Testimony Before the FDA’s Psychopharmacologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee Regarding an Oral Amphetamine Product Intended to be Abuse-Deterrent

View as PDF

In testimony before a joint meeting of the Food and Drug Administration’s (FDA’s) Psychopharmacologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee, Public Citizen argued against approval of AR19, an oral amphetamine product that is intended to be abuse-deterrent, because studies show that the drug is not expected to reduce abuse by injection or intranasal routes.